We discuss the relationship between tale to facts with Releaf’s Chief Operating Officer Graham Woodward and Dr. Anne Katrin Schlag, Head of Research at Drug Science, in this particular episode of the Company of Cannabis Podcast.
Together, they examine how to transition from cliched individual stories to solid, empirical data in the UK, and why this change is crucial to promoting secure, reliable entry to cannabis-based medications.
They explain why facilities like Releaf are investing in data-driven individual attention and quality-of-life surveys, what regulators like NICE are affected, and whether stronger evidence will ultimately allow for communication with the BMA, Royal College, and the wider healthcare program.
Thiȿ discussion is not to be missed for anyone interested įn leaɾning how data αnd individual outcomes cαn help usher iȵ the nȩxt staǥe of English clinical cannabis.
The additional shows are available here.
Online is at website. www. twitter. com/bofc_global twitter. com/bofc_europe
LinkedIn: www.linkedin.com/company/businessofcannabis
Instagram: www.instagram.com/businessofcannabis
Facebook: www.facebook.com/bofcmedia
Apple: http://bofc.me/applepod
Online Podcasts at: https ://bofc. me/bofclive
